<?xml version="1.0" encoding="UTF-8"?>
<p id="Par5">This first-in-human, phase I study of IMGN529 monotherapy was designed to assess the overall safety, pharmacokinetics, and preliminary activity of this novel investigational agent in a dose-finding cohort of patients with relapsed or refractory B-cell NHL.</p>
